10,900 Shares in Applied DNA Sciences, Inc. (NASDAQ:APDN) Acquired by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC purchased a new position in shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,900 shares of the technology company’s stock, valued at approximately $84,000. Schonfeld Strategic Advisors LLC owned about 0.19% of Applied DNA Sciences at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of APDN. Rockefeller Capital Management L.P. bought a new stake in shares of Applied DNA Sciences during the second quarter worth approximately $40,000. Squarepoint Ops LLC acquired a new position in Applied DNA Sciences during the third quarter valued at approximately $78,000. Finally, UBS Group AG grew its holdings in Applied DNA Sciences by 575.6% during the second quarter. UBS Group AG now owns 12,364 shares of the technology company’s stock valued at $100,000 after purchasing an additional 10,534 shares during the period. 7.27% of the stock is owned by institutional investors and hedge funds.

A number of research analysts recently issued reports on the stock. ValuEngine upgraded shares of Applied DNA Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, November 13th. HC Wainwright decreased their price objective on shares of Applied DNA Sciences from $20.00 to $12.00 and set a “buy” rating for the company in a report on Friday, December 18th. Finally, Zacks Investment Research cut shares of Applied DNA Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 2nd.

Applied DNA Sciences stock opened at $5.10 on Friday. The stock has a market capitalization of $28.87 million, a PE ratio of -1.48 and a beta of 1.45. Applied DNA Sciences, Inc. has a twelve month low of $2.52 and a twelve month high of $16.39. The company has a quick ratio of 2.01, a current ratio of 2.13 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $6.41 and a 200-day moving average of $7.82.

Applied DNA Sciences (NASDAQ:APDN) last released its quarterly earnings results on Wednesday, December 16th. The technology company reported ($0.78) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.26). Applied DNA Sciences had a negative net margin of 672.79% and a negative return on equity of 179.48%. Equities analysts anticipate that Applied DNA Sciences, Inc. will post -1.39 EPS for the current fiscal year.

Applied DNA Sciences Profile

Applied DNA Sciences, Inc engages in polymerase chain reaction-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nucleic acid-based therapeutic drug candidates in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T molecular tags, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber DNA.

Featured Story: Do back-end load funds outperform no-load funds?

Institutional Ownership by Quarter for Applied DNA Sciences (NASDAQ:APDN)

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.